ATE227291T1 - Metallkomplexe von wasserlöslichen texaphyrinen - Google Patents

Metallkomplexe von wasserlöslichen texaphyrinen

Info

Publication number
ATE227291T1
ATE227291T1 AT93902982T AT93902982T ATE227291T1 AT E227291 T1 ATE227291 T1 AT E227291T1 AT 93902982 T AT93902982 T AT 93902982T AT 93902982 T AT93902982 T AT 93902982T AT E227291 T1 ATE227291 T1 AT E227291T1
Authority
AT
Austria
Prior art keywords
water
metal complexes
soluble
soluble texaphyrins
texaphyrins
Prior art date
Application number
AT93902982T
Other languages
English (en)
Inventor
Jonathan L Sessler
Gregory W Hemmi
Tarak D Mody
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE227291T1 publication Critical patent/ATE227291T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0485—Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0036—Porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Laminated Bodies (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Conductive Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT93902982T 1992-01-21 1993-01-07 Metallkomplexe von wasserlöslichen texaphyrinen ATE227291T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/822,964 US5252720A (en) 1989-03-06 1992-01-21 Metal complexes of water soluble texaphyrins
PCT/US1993/000107 WO1993014093A1 (en) 1992-01-21 1993-01-07 Metal complexes of water soluble texaphyrins

Publications (1)

Publication Number Publication Date
ATE227291T1 true ATE227291T1 (de) 2002-11-15

Family

ID=25237423

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93902982T ATE227291T1 (de) 1992-01-21 1993-01-07 Metallkomplexe von wasserlöslichen texaphyrinen

Country Status (15)

Country Link
US (9) US5252720A (de)
EP (1) EP0623134B1 (de)
JP (1) JP3530529B2 (de)
KR (1) KR100286963B1 (de)
AT (1) ATE227291T1 (de)
AU (1) AU664877B2 (de)
CA (1) CA2127530C (de)
DE (1) DE69332469T2 (de)
DK (1) DK0623134T3 (de)
ES (1) ES2185627T3 (de)
FI (1) FI107157B (de)
NO (1) NO301828B1 (de)
NZ (1) NZ246795A (de)
PT (1) PT623134E (de)
WO (1) WO1993014093A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162509A (en) * 1989-03-06 1992-11-10 Board Of Regents, The University Of Texas System Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5567687A (en) * 1989-03-06 1996-10-22 University Of Texas Texaphyrins and uses thereof
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5457195A (en) * 1989-12-21 1995-10-10 Board Of Regents, The University Of Texas System Sapphyrin derivatives and conjugates
US5543514A (en) * 1989-12-21 1996-08-06 Board Of Regents, The University Of Texas System Water-soluble sapphyrins
US5594136A (en) * 1989-12-21 1997-01-14 Pharmacyclics, Inc. Texaphyrin solid supports and devices
US5763172A (en) * 1992-01-21 1998-06-09 Board Of Regents, The University Of Texas System Method of phosphate ester hydrolysis
US5595726A (en) * 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5565552A (en) * 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5888997A (en) * 1994-04-14 1999-03-30 Pharmacyclics, Inc. Radiation sensitization using texaphyrins
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5798491A (en) * 1993-06-09 1998-08-25 Board Of Regents, The University Of Texas System Multi-mechanistic chemical cleavage using certain metal complexes
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US6231593B1 (en) * 1994-03-21 2001-05-15 Dusa Pharmaceuticals, Inc. Patch, controller, and method for the photodynamic therapy of a dermal lesion
US5969111A (en) * 1994-04-14 1999-10-19 Board Of Regents, The University Of Texas System Texaphyrins substituted with imidazole are provided
EP0765381B1 (de) * 1994-06-13 1999-08-11 Unilever N.V. Bleichaktivierung
AU733805C (en) * 1994-06-13 2001-12-13 Unilever Plc Bleach activation
US5530122A (en) * 1994-08-23 1996-06-25 Pharmacyclics, Inc. Method of isolating texaphyrins
US5633354A (en) * 1994-09-21 1997-05-27 Pharmacyclics, Inc. Phosphoramidite derivatives of texaphyrins
US5837866A (en) * 1994-09-21 1998-11-17 Board Of Regents, The University Of Texas Phosphoramidite derivatives of macrocycles
US6095147A (en) * 1994-12-01 2000-08-01 The Regents Of The University Of California Method for photo-altering a biological system to improve biological effect
US5703230A (en) * 1994-12-02 1997-12-30 University Of British Columbia Meso-monoiodo-substituted tetramacrocyclic compounds and methods for making and using the same
US6329139B1 (en) 1995-04-25 2001-12-11 Discovery Partners International Automated sorting system for matrices with memory
US5591422A (en) * 1995-06-02 1997-01-07 Pharmacyclics, Inc. Texaphyrin complexes having improved functionalization
US5714328A (en) * 1995-06-07 1998-02-03 Board Of Regents, The University Of Texas System RNA photocleavage using texaphyrins
EP0846003A1 (de) 1995-08-17 1998-06-10 Monsanto Company Verfahren zur diagnostischen bildanalyse unter verwendung von biokonjugaten von metallkomplexen von stickstoffhaltigen makrocyclischen liganden
EP0844889A1 (de) * 1995-08-17 1998-06-03 Monsanto Company Diagnostische bildanalyseverfahrenunter verwendung von metallkomplexen von stickstoff-enthaltenden makrozyklischen liganden
CA2231114A1 (en) 1995-09-06 1997-03-13 The Research Foundation Of State University Of New York Two-photon upconverting dyes and applications
US5776925A (en) * 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
US5883246A (en) * 1996-03-07 1999-03-16 Qlt Phototherapeutics, Inc. Synthesis of polypyrrolic macrocycles from meso-substituted tripyrrane compounds
US5955586A (en) * 1996-03-22 1999-09-21 Sessler; Jonathan L. Highly boronated derivatives of texaphyrins
NZ331977A (en) * 1996-03-26 2000-07-28 Pharmacyclics Inc Texaphyrin in photodynamic therapy of pigment-related lesions
US6375930B2 (en) 1996-06-04 2002-04-23 Board Of Regents, The University Of Texas System Membrane incorporation of texaphyrins
US6022959A (en) * 1996-08-20 2000-02-08 Pharmacyclics, Inc. Nucleic acids internally-derivatized with a texaphyrin metal complex and uses thereof
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6444194B1 (en) 1997-02-14 2002-09-03 Miravant Pharmaceuticals, Inc. Indium photosensitizers for PDT
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US5886173A (en) * 1997-07-30 1999-03-23 Pharmacyclics, Inc. Metallation of macrocycles with 2,4-dicarbonyl-metal complexes
US6022526A (en) * 1997-07-30 2000-02-08 Pharmacyclics, Inc. Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
US20020155999A1 (en) * 1998-04-30 2002-10-24 Han In Suk Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
AU5048400A (en) 1999-05-27 2000-12-18 Monsanto Company Biomaterials modified with superoxide dismutase mimics
CN1762990A (zh) * 1999-06-08 2006-04-26 拉卓拉药物公司 包含氨基氧基的化合价平台分子
US20020049247A1 (en) * 2000-01-12 2002-04-25 Chen James C. Novel treatment for eye disease
WO2001055151A1 (en) * 2000-01-26 2001-08-02 Japan Science And Technology Corporation Polymeric micellar structure
WO2001093914A2 (en) * 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7112671B2 (en) * 2000-08-30 2006-09-26 Pharmacyclics, Inc. Non-symmetric tripyrranes in the synthesis of novel macrocycles
US20030082101A1 (en) * 2001-06-11 2003-05-01 Cavalier Discovery Accelerators for increasing the rate of formation of free radicals and reactive oxygen species
US7928278B2 (en) * 2001-06-12 2011-04-19 University Of Florida Research Foundation, Inc. Method and apparatus for producing near-infrared radiation
DE60229437D1 (de) * 2001-12-13 2008-11-27 Pharmacyclics Inc Verfahren zur beeinflussung neurologischer progression
US6984734B2 (en) 2002-02-26 2006-01-10 Board Of Regents, The University Of Texas System Cyclo[n]pyrroles and methods thereto
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
WO2004050716A2 (en) * 2002-12-04 2004-06-17 Pharmacyclics, Inc. Preparation of metallotexaphyrins
CN1717234A (zh) * 2002-12-06 2006-01-04 爱尔康公司 用于治疗眼紊乱和疾病的超氧化物岐化酶模拟物
US7659301B2 (en) * 2003-04-15 2010-02-09 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
US20050118102A1 (en) * 2003-04-28 2005-06-02 Intematix Corporation Spin resonance heating and/or imaging in medical applications
US20050196466A1 (en) * 2004-03-02 2005-09-08 Pharmacyclics, Inc. Process for inhibiting cell proliferation
WO2005112759A1 (en) * 2004-05-20 2005-12-01 Pharmacyclics, Inc. A method of enhancing visualization of atherosclerotic plaque
WO2006080022A2 (en) * 2005-01-31 2006-08-03 Yeda Research And Development Co. Ltd. Mri contrast agents for diagnosis and prognosis of tumors
US20060171845A1 (en) * 2005-01-31 2006-08-03 Dakota Technologies, Inc. Sensors for measuring analytes
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
WO2006116021A2 (en) * 2005-04-22 2006-11-02 Intematix Corporation Mri technique based on electron spin resonance and endohedral contrast agent
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
WO2007059329A2 (en) * 2005-11-16 2007-05-24 Pharmacyclics, Inc. Methods and compositions for treating cancer
US7528125B2 (en) * 2006-03-20 2009-05-05 Jonathan L. Sessler Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
WO2008020113A1 (en) * 2006-08-18 2008-02-21 Abacus Diagnostica Oy Luminescent lanthanide labelling reagents and their use
US8133474B2 (en) * 2006-09-15 2012-03-13 Massachusetts Institute Of Technology Sensors for fluorescence and magnetic resonance imaging
ES2454974T3 (es) * 2007-06-27 2014-04-14 The General Hospital Corporation Aparato para la inhibición óptica de la terapia fotodinámica
WO2009006075A2 (en) * 2007-06-29 2009-01-08 Board Of Regents, The University Of Texas System Functionalized expanded porphyrins
CZ2007599A3 (cs) * 2007-08-31 2009-03-11 Vysoká škola chemicko-technologická v Praze Použití multimodálních systému pro prípravu prípravku k lécbe a diagnostikování nádorových onemocnení
NZ585999A (en) * 2007-12-07 2011-05-27 Prana Biotechnology Ltd Transition metal complexes for therapy and diagnosis
US8835104B2 (en) 2007-12-20 2014-09-16 Fenwal, Inc. Medium and methods for the storage of platelets
US8802074B2 (en) 2008-11-26 2014-08-12 Board Of Regents, The University Of Texas System Polymers functionalized with ion-specific recognition elements
US9599591B2 (en) 2009-03-06 2017-03-21 California Institute Of Technology Low cost, portable sensor for molecular assays
WO2011140561A1 (en) * 2010-05-07 2011-11-10 Molycorp Minerals Llc Lanthanide-mediated photochemical water splitting process for hydrogen and oxygen generation
EP3662750A1 (de) 2011-04-07 2020-06-10 Fenwal, Inc. Automatisierte verfahren und systeme zur bereitstellung von thrombozytenkonzentraten mit reduziertem restplasmavolumen und medien zur lagerung solcher thrombozytenkonzentrate
AU2013229786B2 (en) 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
JP6282745B2 (ja) 2013-09-12 2018-02-21 ハロザイム インコーポレイテッド 修飾抗上皮成長因子受容体抗体およびその使用法
KR102412203B1 (ko) 2014-06-11 2022-06-23 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 백금 내성을 극복하는데 이용하기 위한 텍사피린-pt(iv) 접합체 및 조성물
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US10335608B2 (en) 2016-04-20 2019-07-02 Theralase Technologies, Inc. Photodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics
MA51184A (fr) 2017-12-15 2020-10-21 Juno Therapeutics Inc Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
CN108586469B (zh) * 2018-03-19 2021-05-07 西北师范大学 一种抑制硫化镉光腐蚀的方法
KR20230067608A (ko) 2020-08-14 2023-05-16 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 망간 화학 요법, 광음향 이미징, 및 광열 요법을 위한 텍사피린 유도체

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2308252A1 (de) * 1973-02-20 1974-08-22 Basf Ag Verfahren zur herstellung von mesotetraarylporphinen
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4613322A (en) * 1982-12-08 1986-09-23 Edelson Richard Leslie Method and system for externally treating the blood
JPS61275228A (ja) * 1985-03-14 1986-12-05 バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド 治療用タンパク組成物中のビ−ルスの光動的不活性化
US4977177A (en) * 1985-04-30 1990-12-11 Nippon Petrochemicals Company, Ltd. Tetrapyrrole polyaminomonocarboxylic acid therapeutic agents
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4899755A (en) * 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
CA1315780C (en) * 1986-01-17 1993-04-06 Yozo Fukuda Porphyrin derivatives
US4915683A (en) * 1986-11-21 1990-04-10 The Medical College Of Wisconsin, Inc. Antiviral method, agents and apparatus
US4883790A (en) * 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US4878891A (en) * 1987-06-25 1989-11-07 Baylor Research Foundation Method for eradicating infectious biological contaminants in body tissues
US5250668A (en) * 1988-01-11 1993-10-05 Morgan Alan R Production and use of porphyrin derivatives and of compositions containing such derivatives
US5162509A (en) * 1989-03-06 1992-11-10 Board Of Regents, The University Of Texas System Process for preparing expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5041078A (en) * 1989-03-06 1991-08-20 Baylor Research Foundation, A Nonprofit Corporation Of The State Of Texas Photodynamic viral deactivation with sapphyrins
US5272142A (en) * 1989-03-06 1993-12-21 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles and methods for treating tumors
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5256399A (en) * 1989-03-06 1993-10-26 Board Of Regents, The University Of Texas System Aromatic pentadentate expanded porphyrins in magnetic resonance imaging
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5257970A (en) * 1992-04-09 1993-11-02 Health Research, Inc. In situ photodynamic therapy

Also Published As

Publication number Publication date
CA2127530C (en) 2001-05-29
ES2185627T3 (es) 2003-05-01
US5432171A (en) 1995-07-11
US5475104A (en) 1995-12-12
WO1993014093A1 (en) 1993-07-22
US5733903A (en) 1998-03-31
CA2127530A1 (en) 1993-07-22
NZ246795A (en) 1996-02-27
AU664877B2 (en) 1995-12-07
NO942719L (no) 1994-09-19
DE69332469T2 (de) 2003-07-10
DE69332469D1 (de) 2002-12-12
DK0623134T3 (da) 2003-03-17
US5252720A (en) 1993-10-12
US5504205A (en) 1996-04-02
JP3530529B2 (ja) 2004-05-24
US5439570A (en) 1995-08-08
EP0623134A1 (de) 1994-11-09
AU3436793A (en) 1993-08-03
NO301828B1 (no) 1997-12-15
PT623134E (pt) 2003-03-31
FI943445A7 (fi) 1994-07-20
JPH07503009A (ja) 1995-03-30
US5569759A (en) 1996-10-29
US5451576A (en) 1995-09-19
KR100286963B1 (ko) 2001-04-16
US5994535A (en) 1999-11-30
NO942719D0 (no) 1994-07-20
EP0623134B1 (de) 2002-11-06
FI107157B (fi) 2001-06-15
FI943445A0 (fi) 1994-07-20

Similar Documents

Publication Publication Date Title
ATE227291T1 (de) Metallkomplexe von wasserlöslichen texaphyrinen
ES2020011A6 (es) Metodo de sintesis de composiciones que comprenden al menos un butano fenolico.
ATE194916T1 (de) Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren
DE69703294D1 (de) Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten
DK0730441T3 (da) Deskvamationspræparater, der indeholder salicylsyre og zwitterioniske forbindelser
DE69936444D1 (de) Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie
ATE70449T1 (de) Zusammensetzungen von katecholischen butanen mit zink.
MX9306960A (es) Composiciones de extracto de corteza de roble, compositiones sinteticasrelacionadas, y metodo para su utilizacion.
IL134445A0 (en) A method of preventing or treating estrogen-dependent diseases and disorders
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
DE69633178D1 (de) Eisenverbindungen, zusammensetzungen, herstellungsverfahren und verwendungen davon
MX9301083A (es) Complejos de quelato y procesos para su preparacion.
DK1014990T3 (da) Antitumorkombination af 3 amino-1,2,4 benzotriazin-1,4 dioxid/paclitaxel/platin
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
ATE198543T1 (de) Haarbehandlungsmittel
NO20050640L (no) Rutenium anticancer komplekser
NZ242748A (en) Compositions containing a pseudocatalase for treating depigmentation disorders
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
ZA9711468B (en) New use of comt inhibitors
NO961204D0 (no) Triaryletylenderivater for anvendelse innen terapi
RU94024337A (ru) Антиметастатическое средство
ES2088682T3 (es) Agente bronceador de la piel.
DE3160437D1 (en) Water soluble polyesters and polycarbonates for use as antitumor agents
FI965171L (fi) Oksatsofosforiinien, esimerkiksi ifosfamidin, enantiomeerien käyttö kasvainten hoidossa sivuvaikutuksien vähentämiseksi

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0623134

Country of ref document: EP

REN Ceased due to non-payment of the annual fee